Northwest Bio halts enrollment for glioblastoma vax PhIII trial; Germany grants €30 million to East African Community for vaccines, health supply chain management;

> Enrollment for Northwest Bio's ($NWBO) Phase III trial of DCVax for glioblastoma has temporarily halted so its investigators can submit new information for regulatory review. Release

> Germany granted €70 million ($79 million) to the East African Community, €30 million ($34 million) of which will fund vaccines and health supply chain management. More

> There hasn't been a poison ivy vaccine since the 1980s, which was discontinued because it didn't meet new FDA efficacy standards. But an allergist in Pennsylvania is working on a new vaccine, made with poison ivy extract and ethanol. Story

> Pakistan launched a new polio vaccine to accelerate its campaign to eradicate the disease by 2016. Report

Suggested Articles

Sanofi lost an appeal challenging the ban on its dengue vaccine Dengvaxia in the Philippines, despite an ongoing outbreak there.

After countless headlines from a Dengvaxia safety scandal in the Philippines, officials are now considering using the Sanofi vaccine again.

Merck's oncology superstar Keytruda has been stealing the spotlight, but in vaccines, the drugmaker has growth figures to tout.